Ethoheptazine

Ethoheptazine
Systematic (IUPAC) name
Ethyl 1-methyl-4-phenylazepane-4-carboxylate
Clinical data
Trade names Equagesic
Oral
Identifiers
77-15-6 
None
PubChem CID 6469
DrugBank DB08988 
ChemSpider 6225 Yes
UNII 3A4G3A848U Yes
ChEMBL CHEMBL170797 
Synonyms Zactane
Chemical data
Formula C16H23NO2
261.36 g/mol
  (what is this?)  (verify)

Ethoheptazine[1] (trade name Zactane) is an opioid analgesic from the phenazepine family. It was invented in the 1950s[2] and is related to other drugs such as proheptazine and pethidine.[3]

Ethoheptazine produces similar effects to other opioids, including analgesia, sedation, dizziness and nausea.[4] It was sold by itself as Zactane, and is still available as a combination product with acetylsalicylic acid and meprobamate as Equagesic, which is used for the treatment of conditions where both pain and anxiety are present.[5]

Its no longer sold in the United States however it may be sold again if the law is changed to remove the drug from the CSD.

References

  1. ↑ ES Patent 310184
  2. ↑ Batterman RC, Golbey M, Grossman AJ, Leifer P. Analgesic effectiveness of orally administered ethoheptazine in man. American Journal of Medical Sciences. 1957 Oct;234(4):413-9.
  3. ↑ Diamond J, Bruce WF, Tyson FT. Synthesis and Properties of the Analgesic DL-α-1,3-dimethyl-4-phenyl-4-propionoxyazacycloheptane (Proheptazine). Journal of Medicinal Chemistry. 1964 Jan;7:57-60.
  4. ↑ Cinelli P, Zucchini M. Current pharmaco-therapeutic possibilities in the treatment of pain. Experiments with ethoeptazine. (Italian). Minerva Medica. 1962 Mar 3;53:637-42.
  5. ↑ Scheiner JJ, Richards DJ. Treatment of musculoskeletal pain and associated anxiety with an ethoheptazine-aspirin-meprobamate combination (equagesic): a controlled study. Current Therapeutic Research, Clinical and Experimental. 1974 Sep;16(9):928-36.